Investors focused on the Medical space have likely heard of Option Care Health (OPCH - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Option Care Health is a member of the Medical sector. This group includes 977 individual stocks and currently holds a Zacks Sector Rank of #16. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. OPCH is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for OPCH's full-year earnings has moved 44.14% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, OPCH has gained about 20.97% so far this year. In comparison, Medical companies have returned an average of 2.71%. This shows that Option Care Health is outperforming its peers so far this year.
Looking more specifically, OPCH belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 16 individual stocks and currently sits at #216 in the Zacks Industry Rank. On average, this group has lost an average of 3.84% so far this year, meaning that OPCH is performing better in terms of year-to-date returns.
OPCH will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Option Care Health (OPCH - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Option Care Health is a member of the Medical sector. This group includes 977 individual stocks and currently holds a Zacks Sector Rank of #16. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. OPCH is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for OPCH's full-year earnings has moved 44.14% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, OPCH has gained about 20.97% so far this year. In comparison, Medical companies have returned an average of 2.71%. This shows that Option Care Health is outperforming its peers so far this year.
Looking more specifically, OPCH belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 16 individual stocks and currently sits at #216 in the Zacks Industry Rank. On average, this group has lost an average of 3.84% so far this year, meaning that OPCH is performing better in terms of year-to-date returns.
OPCH will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on OPCH - FREE